145 related articles for article (PubMed ID: 34583363)
1. Comparison of Efficacy and Safety between Conbercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: A Meta-Analysis of Randomized Controlled Trials.
Wang X; Yu C; Yang J; Liu Y; Xu Y; Li W
Ophthalmic Res; 2022; 65(2):140-151. PubMed ID: 34583363
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis.
Wang L; Zhang C; Hua R
Drug Des Devel Ther; 2018; 12():3625-3633. PubMed ID: 30464394
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study.
Cui J; Sun D; Lu H; Dai R; Xing L; Dong H; Wang L; Wei D; Jiang B; Jiao Y; Jablonski MM; Charles S; Gu W; Chen H
Eye (Lond); 2018 Feb; 32(2):391-399. PubMed ID: 28937147
[TBL] [Abstract][Full Text] [Related]
4. Ranibizumab and conbercept for treating wet age-related macular degeneration in China: A systematic review and meta-analysis.
Pengfei J; Hanyu T; Qinghua P
Medicine (Baltimore); 2021 Dec; 100(48):e27774. PubMed ID: 35049171
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion.
Liu W; Li Y; Cao R; Bai Z; Liu W
Medicine (Baltimore); 2020 May; 99(21):e20222. PubMed ID: 32481293
[TBL] [Abstract][Full Text] [Related]
6. Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis.
Cui C; Lu H
Clin Interv Aging; 2018; 13():51-62. PubMed ID: 29343949
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis.
Tricco AC; Thomas SM; Lillie E; Veroniki AA; Hamid JS; Pham B; Lee T; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Janoudi G; Muni RH; Francisconi CLM; Richter T; Straus SE
Syst Rev; 2021 Dec; 10(1):315. PubMed ID: 34930439
[TBL] [Abstract][Full Text] [Related]
8. Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis.
Zhou P; Zheng S; Wang E; Men P; Zhai S
Front Pharmacol; 2021; 12():696201. PubMed ID: 34712132
[No Abstract] [Full Text] [Related]
9. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
Xu Y; Rong A; Xu W; Niu Y; Wang Z
BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
[TBL] [Abstract][Full Text] [Related]
11. One-Year Outcomes of Intravitreal Conbercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration.
Li X; Zhang Y; Zhang Z; Xu Y; Zhang M
Ophthalmic Res; 2019; 62(2):93-100. PubMed ID: 31121579
[TBL] [Abstract][Full Text] [Related]
12. Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study.
Liu K; Song Y; Xu G; Ye J; Wu Z; Liu X; Dong X; Zhang M; Xing Y; Zhu S; Chen X; Shen Y; Huang H; Yu L; Ke Z; Rosenfeld PJ; Kaiser PK; Ying G; Sun X; Xu X;
Am J Ophthalmol; 2019 Jan; 197():156-167. PubMed ID: 30148987
[TBL] [Abstract][Full Text] [Related]
13. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
14. Conbercept for patients with age-related macular degeneration: a systematic review.
Zhang J; Liang Y; Xie J; Li D; Hu Q; Li X; Zheng W; He R
BMC Ophthalmol; 2018 Jun; 18(1):142. PubMed ID: 29902977
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis.
Yen WT; Wu CS; Yang CH; Chen YH; Lee CH; Hsu CR
Sci Rep; 2024 Jan; 14(1):2485. PubMed ID: 38291069
[TBL] [Abstract][Full Text] [Related]
17. The Evaluation of a Two-Year Outcome of Intravitreal Conbercept versus Ranibizumab for Pathological Myopic Choroidal Neovascularization.
Chen C; Yan M; Huang Z; Song YP
Curr Eye Res; 2020 Nov; 45(11):1415-1421. PubMed ID: 32191134
[No Abstract] [Full Text] [Related]
18. SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Jin E; Bai Y; Luo L; Huang L; Zhu X; Ding X; Qi H; Zhao M
Retina; 2017 May; 37(5):971-977. PubMed ID: 27617537
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Woo SJ; Veith M; Hamouz J; Ernest J; Zalewski D; Studnicka J; Vajas A; Papp A; Gabor V; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Bressler NM
JAMA Ophthalmol; 2021 Jan; 139(1):68-76. PubMed ID: 33211076
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study.
Li X; Xu G; Wang Y; Xu X; Liu X; Tang S; Zhang F; Zhang J; Tang L; Wu Q; Luo D; Ke X;
Ophthalmology; 2014 Sep; 121(9):1740-7. PubMed ID: 24793528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
